Posted in

India’s NexCAR19: Revolutionizing Cancer Treatment Affordably

•Posted inMedical Updates
Doctor studying international diabetes care guidelines like ADA, NICE, and WHO for clinical practice and global career advancement

India has achieved a monumental milestone in biotechnology and cancer care with the unveiling of NexCAR19, the nation’s first Indigenous CAR-T Therapy. Prime Minister Narendra Modi introduced this groundbreaking innovation, developed by ImmunoACT, an IIT Bombay spin-off, during the Emerging Science, Technology & Innovation Conclave (ESTIC) 2025 in Delhi. Consequently, this development promises to make advanced cancer immunotherapy more affordable and accessible for patients across the country.

Understanding Indigenous CAR-T Therapy

Chimeric Antigen Receptor (CAR) T-cell therapy represents a cutting-edge form of immunotherapy. It essentially re-programs a patient’s own immune cells to effectively fight cancer. This complex process involves collecting a patient’s T-cells, genetically modifying them in a laboratory to express CARs that target specific cancer cell antigens (like CD19), and then reinfusing these enhanced cells back into the patient. Subsequently, these modified T-cells actively identify and destroy cancer cells. This advanced treatment has shown remarkable success in treating blood cancers, including Acute Lymphocytic Leukemia (ALL) and lymphomas, particularly in patients with limited treatment options.

NexCAR19 stands out as the world’s first humanized CAR-T therapy developed entirely in India, exemplifying a truly “Made in India, for the world” innovation. Furthermore, this innovative “living drug” aims to provide gene therapies that are both affordable and accessible, while upholding global standards of safety and scientific rigor. Significantly, NexCAR19 costs approximately $50,000 (around Rs 40 lakh), which is about one-tenth the cost of similar therapies in the United States, typically priced at $400,000.

Promising Clinical Outcomes and Support

Clinical trials for NexCAR19, conducted at the Tata Memorial Centre (TMC), have yielded encouraging results. For instance, in trials involving 64 patients with advanced lymphoma or leukemia, 67% of patients experienced a notable decrease in their cancer, with approximately half achieving complete remission. The therapy also demonstrated an improved safety profile, showing a lower incidence of cytokine release syndrome (CRS) and no reported neurotoxicity, which marks a significant improvement over other commercially approved CD19-directed CAR-T cell therapies.

ImmunoACT originated from the Society for Innovation and Entrepreneurship (SINE), IIT Bombay’s technology business incubator. It received crucial early-stage support under BIRAC’s BioNest initiative, including funding, mentorship, and access to advanced research infrastructure. The Department of Biotechnology (DBT) and Biotechnology Industry Research Assistance Council (BIRAC) have also provided significant backing for the project, including partial support for the first CAR-T clinical trials initiated in 2021 at ACTREC, Tata Memorial Hospital.

Expanding Accessibility and Future Directions

To scale up this therapeutic breakthrough, DBT’s Biomanufacturing initiative, under the BioE3 Policy, provided funding to ImmunoACT. This support helps establish a 200L GMP lentiviral vector and plasmid production platform. This facility will enable large-scale, high-quality production using advanced bioreactor technologies, thus facilitating the manufacture of gene delivery vectors for up to 1,000 patients annually.

The DBT continues to actively promote both early and late-stage translational research in CAR-T and other immunotherapies. Their objective is to develop indigenous solutions for a wide range of cancers, including multiple myeloma, relapsed or refractory B-cell leukemia, and glioblastoma, while simultaneously addressing therapy-related toxicities. NexCAR19 is currently available in over 30 hospitals across more than 10 cities in India. Therefore, with NexCAR19, India joins a select group of nations developing advanced cell and gene therapies, showcasing its growing capacity to deliver cutting-edge, affordable cancer care and fostering a new era of biotech innovation and self-reliance.

Frequently Asked Questions

Q1: What is NexCAR19?

NexCAR19 is India’s first indigenous CAR-T cell therapy, developed by ImmunoACT, an IIT Bombay spin-off. It is a personalized immunotherapy that modifies a patient’s own immune cells to target and destroy cancer cells, primarily for blood cancers like leukemia and lymphoma.

Q2: How does NexCAR19 make CAR-T cell therapy more affordable?

NexCAR19 is priced significantly lower than international CAR-T cell therapies, costing approximately $50,000 in India compared to around $400,000 in the United States. This dramatic cost reduction enhances accessibility for a broader patient population.

Q3: Which types of cancer can NexCAR19 treat?

NexCAR19 is approved for the treatment of relapsed or refractory B-cell lymphomas and leukemia. Ongoing research also explores its potential for other cancers, including multiple myeloma and glioblastoma.

References

  1. India Unveils Its First Indigenous CAR-T Cell Therapy, Paving the Way forAffordable Cancer Immunotherapy – ETHealthworld
  2. India’s First Homegrown CAR T-Cell Therapy – NCI – National Cancer Institute
  3. India’s Indigenous CAR T-Cell Therapy Revolutionizes Cancer Treatment at One-Tenth Global Cost – MedPath
  4. A Discount on the Cost of Cancer: India’s Homegrown CAR-T Cell Therapy – PMC – NIH
  5. NexCAR 19 Cancer Therapy, The First Living Drug in India – MrMed
  6. CAR-T cell therapy in India 2024 | Israeli Hospitals Ltd.
  7. NexCAR19 CAR T-Cell Therapy for Cancer Treatment in India: Costs, Best Doctors & Hospitals – CureIndia
  8. CAR T-Cell Therapy in India – Cost, Treatment & Patient Guide 2025 – Denvax
  9. PM Modi Unveils India’s First Quantum Chips and Indigenous CAR-T Cancer Therapy at ESTIC 2025 PM Modi Unveils India’s First Quantum Chips and Indigenous CAR-T Cancer Therapy at ESTIC 2025 – The Impressive Times
  10. ImmunoACT announces CDSCO approval of India’s first CAR-T cell therapy NexCAR19
  11. India’s First Clinical Trial for Affordable CAR-T Cell Therapy Launched
  12. India launches Immunoact’s homegrown NexCAR19 for cancer | BioWorld
  13. Cancer remission achieved after commercial use of NexCAR19, India’s first indigenous CAR-T cell therapy | Current Affairs | Vision IAS
  14. CAR-T Cell Therapy Cost in India – Dr. Rahul Bhargava
  15. India’s 1st CAR-T cell therapy developed by ImmunoACT gets CDSCO nod
  16. ImmunoACT announces the approval of India’s first CAR-T cell therapy ‘NexCAR19’
  17. NexCAR19-Patients – ImmunoACT
  18. ImmunoACT – India’s Pioneer in Cell & Gene Therapies
  19. NexCAR19-HCP – ImmunoACT

Disclaimer: This article was automatically generated from publicly available sources and is provided for informational and educational purposes only. OC Academy does not exercise editorial control or claim authorship over this content. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider and refer to current local and national clinical guidelines.